

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2877)

SUPPLEMENTAL ANNOUNCEMENT

**CONNECTED TRANSACTIONS
AND
CONTINUING CONNECTED TRANSACTIONS**

Reference is made to the announcement of China Shineway Pharmaceutical Group Limited (the “**Company**”) dated 17 December 2020 in relation to the entering into of connected transactions and continuing connected transactions of the Company (the “**Announcement**”). Unless the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcement.

This announcement is made to provide supplemental information on the identity of the ultimate beneficial owner of Shineway Sanhe.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the remaining 70% of interest in Shineway Sanhe is held by Yangpu KangYi Investment Co., Ltd.* (洋浦康意投資有限公司), of which its ultimate beneficial owner is Ms. Wang Zhihua. Ms. Wang Zhihua is a director of Shineway Pharmaceutical and Hebei Shineway (both of them being indirect wholly-owned subsidiaries of the Company), and is therefore a connected person of the Company at the subsidiary level under the Listing Rules. As disclosed in the Announcement, Ms. Ren, the spouse of Mr. Li, indirectly owns 30% of the interest in Shineway Sanhe. Shineway Sanhe, by virtue of being an associate of Mr. Li and Ms. Wang Zhihua, is therefore a connected person of the Company under the Listing Rules.

Save as disclosed above, all other information as set out in the Announcement remain unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 18 December 2020

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Cheung Chun Yue Anthony.

**For identification purpose only*